

**S2 Fig.** Seroconversion rates following each vaccination. Spike-specific binding antibody seroconversion rates before and after each dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients with solid cancers and healthcare workers. Seroconversion rates (%) were compared using the Pearson's chi-squared test or Fisher's exact method. The CamRNA group received a primary series of mRNA vaccines (either BNT162b2 or mRNA-1273); the Ca-AdV group received a primary series of adenovirus vector vaccines (AZD1222); HCW-mRNA and HCW-AdV are groups of age-matched healthcare workers who received a primary series of mRNA vaccines and adenovirus vector vaccines, respectively. ns, no significance; \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.